First Patient Dosed in Phase 1/2 Trial Evaluating YH001 in Combination with Envafolimab and Doxorubicin in Front Line Sarcoma Patients
Beijing, China and San Diego, CA, November 21, 2022 - Eucure (Beijing) Biopharma Co., Ltd. (“Eucure Biopharma”), a wholly owned subsidiary of Biocytogen Pharmaceuticals (Beijing)…
Read more
Selecting the Right Platform for Your Antibody Discovery Project
Contributed by John Charpentier, Ph.D. and Li Hui, M.D., Ph.D. The variety of technology platforms available for therapeutic antibody discovery can be both exciting and…
Read more
BioMice’s Target Humanized Mouse Models Enable Preclinical Toxicity Studies to Support IND Approval
In February 2022, to meet the challenge of NHP shortage, the Food and Drug Administration (FDA) published a new guideline - Nonclinical Considerations for Mitigating…
Read more
Neuroscience 2022
Join us at booth #2703 at Neuroscience 2022 in San Diego, CA, November 12-16! Learn more about our latest model and service offerings. Whether you…
Read more
Biocytogen to Deliver 1 Oral and 3 Poster Presentations at PEGS EUROPE 2022, Introducing RenLite Platform, TCR-mimic Platform, and Antibody Assets
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315) announced today that the company will present at the upcoming Protein & Antibody Engineering Summit (PEGS EUROPE)…
Read more
37th SITC Annual Meeting 2022
Join us at the 37th Society for Immunotherapy of Cancer (SITC) Annual Meeting in Boston, MA! Our booth will be open to greet visitors on…
Read more
Biocytogen to Present Progress of Antibody Assets and Five Fully Human Antibody Discovery Platforms at ChinaBio 2022
Biocytogen’s BD & Licensing team will attend and present at the upcoming ChinaBio virtual conference on November 8-11, 2022. The company will give an oral…
Read more
30% OFF Antibody Discovery services!
Get started on your antibody discovery project as the year comes to a close! All projects* for the month of December will receive 30% OFF…
Read more
Eucure Biopharma, a Subsidiary of Biocytogen, Announces Partnership with ISU ABXIS for the Development of Tri-specific Antibodies using YH003 Antibody Sequence
YH003 is an agonistic anti-CD40 IgG2 monoclonal antibody with best-in-class potential. YH003 in combination with PD-1 are being dosed in phase II multi-regional clinical trials…
Read more
Festival of Biologics Basel 2022
Speaker: Qingcong Lin, CEO, Biocytogen Boston Corporation Date: Nov 3, 2022 Time: 12:20 PM CET/ 6:20 AM EDT Next-Generation Humanized Models Accelerate Antibody Discovery, Lead Characterization &…
Read more